Published in AIDS Weekly, July 21st, 1997
Early clinical trials of the drug 1592 indicate it penetrates the central nervous system, according to a statement by Glaxo Wellcome Inc. Researchers are studying the drug to examine its effect on HIV related neurological diseases.
The U.S. Food and Drug Administration (FDA) agreed to make the drug available to desperate children while scientists continue testing. Only a limited number of patients who meet very strict criteria are allowed into clinical trials of drugs. Dying patients outside...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.